The prevalence of hyperlipoproteinaemia in vascular disease
Lawrie, T.D.; Lorimer, A.R.; Ballantyne, D.; Jubb, J.S.; Morgan, H.G.
Postgraduate Medical Journal 51(8): 7-15
1975
ISSN/ISBN: 0032-5473 PMID: 1221381 Document Number: 85078
Document emailed within 1 workday
Related Documents
Farid, N.R.; Dickinson, P.H.; MacNeal, I.F.; Anderson, J. 1974: Hyperlipoproteinaemia in peripheral arterial disease in the north of England Journal of Cardiovascular Surgery 15(3): 366-372Migdalis, I.N.; Dimakopoulos, N.; Kourti, A.; Tolis, A.; Koutoulidis, K.; Samartzis, M. 1994: The prevalence of peripheral vascular disease in type 2 diabetic patients with and without proteinuria International Angiology: a Journal of the International Union of Angiology 13(3): 229-232
Vega, A.; Pérez García, R.; Abad, S.; Verde, E.; López Gómez, J.M.; Jofré, R.; Puerta, M.; Rodríguez, P. 2008: Peripheral vascular disease: prevalence, mortality and relationship with inflammation in hemodialysis Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 28(3): 311-316
Migdalis, I.N.; Kourti, A.; Voudouris, G.; Likoudi, A.; Samartzis, M. 1990: The prevalence of peripheral vascular disease in sulfonylurea treated diabetic patients with proteinuria International Angiology: a Journal of the International Union of Angiology 9(4): 271-273
Collet, J.P.; Allali, Y.; Borentain, M.; Payot, L.; Raoux, F.; Cacoub, P.; Leys, D.; Alperovitch, A.; Montalescot, G. 2005: Prevalence of asymptomatic atherothrombotic lesions and risk of vascular events in patients with documented coronary artery disease Archives des Maladies du Coeur et des Vaisseaux 98 Spec no 4: 31-54
Wang, H-yu. 2010: Vascular medicine:vascular health evaluation and vascular disease prevention and medication Zhonghua Yi Xue Za Zhi 90(30): 2092-2093
Zanchetti, A. 1992: Has antihypertensive treatment prevented vascular disease or vascular events? Journal of Cardiovascular Pharmacology 19 Suppl. 3: S1-S5
Majewska, K.; Ciswicka-Sznajdermanowa, M.; Czechowicz-Janicka, K. 1977: Eye changes in hyperlipoproteinaemia type Ii Klinika Oczna 47(4): 175-177
Hellström, K.; Einarsson, K. 1977: Bile acid metabolism in hyperlipoproteinaemia Clinics in Gastroenterology 6(1): 103-128
Schade, R.W.; Laar A van't; Jansen, A.P. 1973: Treatment of type Ii hyperlipoproteinaemia with cholestyramine Netherlands Journal of Medicine 16(6): 254-259
Novikov, I.; Olmer, L.; Keinan-Boker, L.; Silverman, B.; Robinson, E.; Freedman, L.S. 2020: A modified Prevalence Incidence Analysis Model method may improve disease prevalence prediction Journal of Clinical Epidemiology 123: 18-26
Micheli, H.; Pometta, D.; Gustafson, A. 1980: Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins a and B in type IIa HLP La Nouvelle Presse Medicale 9(49): 3759-3762
Gariot, P.; Seurot, J.M.; Pointel, J.P.; Contet-Audonneau, J.L.; Gay, G.; Drouin, P.; Debry, G. 1982: The liver and primary type IV hyperlipoproteinaemia: a pathological study Human Nutrition. Clinical Nutrition 36(5): 351-361
Nye, E.R.; Sutherland, W.H.; Temple, W.a. 1980: The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate New Zealand Medical Journal 92(671): 345-349
Potter, J.M.; Macdonald, W.B. 1979: Primary type I hyperlipoproteinaemia--a metabolic and family study Australian and New Zealand Journal of Medicine 9(6): 688-693
Ramaswami, P.K.; Senior, D.C. 1979: Klinefelter's syndrome with agenesis of kidney, diabetes, hyperlipoproteinaemia and stroke British Journal of Clinical Practice 33(5): 142-143
Canetti, M.; Moreira, M.; Mas, R.; Illnait, J.; Fernandez, L.; Fernandez, J.; Diaz, E.; Castano, G. 1995: A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia International Journal of Clinical Pharmacology Research 15(4): 159-165
García-Gómez, C.; Martín-Martínez, M.ía.A.; Fernández-Carballido, C.; Castañeda, S.; González-Juanatey, C.; Sanchez-Alonso, F.; González-Fernández, M.ía.J.; Sanmartí, R.; García-Vadillo, J.ús.A.; Fernández-Gutiérrez, B.ín.; García-Arias, M.; Manero, F.J.; Senabre, J.é M.; Rueda-Cid, A.; Ros-Expósito, S.; Pina-Salvador, J.é M.; Erra-Durán, A.; Möller-Parera, I.; Llorca, J.; González-Gay, M.A. 2019: Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project Clinical and Experimental Rheumatology 37(5): 774-782
Ramachandran, A.; Snehalatha, C.; Satyavani, K.; Latha, E.; Sasikala, R.; Vijay, V. 1999: Prevalence of vascular complications and their risk factors in type 2 diabetes Journal of the Association of Physicians of India 47(12): 1152-1156
Bower, S. 1982: Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure Journal of Pharmacy and Pharmacology 34(2): 102-106